Dextrin-coated zinc substituted cobalt-ferrite nanoparticles as an MRI contrast agent: In vitro and in vivo imaging studies

2015 ◽  
Vol 129 ◽  
pp. 15-20 ◽  
Author(s):  
N. Sattarahmady ◽  
T. Zare ◽  
A.R. Mehdizadeh ◽  
N. Azarpira ◽  
M. Heidari ◽  
...  
Keyword(s):  
Contrast Agent ◽  
In Vivo Imaging ◽  
Cobalt Ferrite ◽  
Ferrite Nanoparticles ◽  
Mri Contrast Agent ◽  
Imaging Studies ◽  
Mri Contrast ◽  
Cobalt Ferrite Nanoparticles

scholarly journals Study on Establishing Reference Safe Concentrations of MRI Contrast Agents for Optimized Images: Paramagnetic Gd-DTPA-BMEA and Superparamagnetic Ferucarbotran

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast Agent ◽  
In Vitro Experiments ◽  
Mri Contrast ◽  
In Vivo Experiments ◽  
Contrast Agent Injection

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.

scholarly journals Superparamagnetic cobalt ferrite nanoparticles as T 2 contrast agent in MRI: in vitro study

2020 ◽  
Vol 14 (5) ◽  
pp. 396-404 ◽  
Author(s):  
Zahra Mohammadi ◽  
Neda Attaran ◽  
Ameneh Sazgarnia ◽  
Seyed Ali Mousavi Shaegh ◽  
Alireza Montazerabadi
Keyword(s):  
Contrast Agent ◽  
Cobalt Ferrite ◽  
In Vitro Study ◽  
Ferrite Nanoparticles ◽  
Vitro Study ◽  
Cobalt Ferrite Nanoparticles

Development of Gold-Coated Magnetic Nanoparticles as a Potential MRI Contrast Agent

NANO ◽  
2015 ◽  
Vol 10 (04) ◽  
pp. 1550048 ◽  
Author(s):  
Ali Reza Montazerabadi ◽  
Mohammad Ali Oghabian ◽  
Rasoul Irajirad ◽  
Samad Muhammadnejad ◽  
Davoud Ahmadvand ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Early Stage ◽  
Superparamagnetic Iron Oxide ◽  
In Vitro Cytotoxicity ◽  
Mri Contrast Agent ◽  
Core Shell ◽  
Mri Contrast ◽  
Shell Particles

Gold-coated superparamagnetic iron oxide nanoparticles (SPIONs) coated with methyl-polyethylene glycol (mPEG) are synthesized and investigated as a magnetic resonance (MR) imaging contrast agent. The synthesized mPEG-core@shells are characterized by UV-visible spectroscopy, transmission electron microscopy (TEM), dynamic light scattering (DLS), vibrating sample magnetometry (VSM), zeta-potential analysis and X-ray diffraction (XRD). In addition, the transverse relaxivity of the mPEG-core@shells is measured using a 3 T MRI scanner. The cytotoxicity of the mPEG-core@shells is tested in the LNCaP cell line using an 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The results show that the mPEG-core@shell particles are semispherical with hydrodynamic size of ∼ 65 nm and a transverse relaxivity of 162.3 mM-1 S-1. The mPEG-core@shell particles demonstrate good stability in biological media without any significant in vitro cytotoxicity under high cellular uptake conditions. Finally, in vivo imaging shows that mPEG-core@shells are a potential contrast agent for use in early-stage detection.

scholarly journals SPIO-loaded Nanostructured Lipid Carriers as Liver Targeted Molecular T2-Weighted MRI Contrast Agent

2018 ◽  
Author(s):  
Xiuliang Zhu ◽  
Chenying Lu ◽  
Zuhua Wang ◽  
Ying Chen ◽  
Liyong Jie ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Ultrasonic Method ◽  
Nanostructured Lipid Carriers ◽  
Mri Contrast Agent ◽  
Nanostructured Lipid Carrier ◽  
Mri Contrast ◽  
Hepatic Diseases ◽  
Targeting Ability

The aim of this study was to develop a novel nanostructured lipid carriers (NLCs) with hepatocytes targeting as carriers for the magnetic resonance imaging (MRI) contrast agent (i.e., magnetic nanostructured lipid carriers, MNLCs), and to evaluate the targeting ability of the MNLCs with T2-weighted MRI both in vitro and in vivo. Here, the galactose-octadecylamine (Gal-ODA) conjugates were synthesized by chemical coupling reaction between lactose acid (LA) and octadecylamine (ODA). Then the superparamagnetic iron oxide (SPIO) loaded nanostructured lipid carrier (conjugated by Gal-ODA, Gal-NLC-SPIO) was prepared by emulsification-ultrasonic method using monoglyceride as lipid materials. The Gal-NLC-SPIO with a diameter of about 50 nm could specifically internalize into LO2 (human hepatic cell line) cells. In vitro MRI results also proved the specific targeting ability of Gal-NLC-SPIO to LO2 cells. The in vivo MR imaging experiments using an orthotopic intrahepatic xenograft tumor model further validated the hepatocytes targeted effect of Gal-NLC-SPIO. The results of this study suggested that Gal-NLC-SPIO can be used as a contrast agent to aid in the diagnosis of hepatic diseases.

Synthesis and in vitro and in vivo evaluation of manganese(III) porphyrin–dextran as a novel MRI contrast agent

2009 ◽  
Vol 19 (23) ◽  
pp. 6675-6678 ◽  
Author(s):  
Zhi Zhang ◽  
Rui He ◽  
Kun Yan ◽  
Qian-ni Guo ◽  
Yun-guo Lu ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Mri Contrast Agent ◽  
In Vivo Evaluation ◽  
Mri Contrast

Synthesis and Evaluation of a Biocompatible Macromolecular Gadolinium Compound as a Liver-Specific Contrast Agent for MRI

2017 ◽  
Vol 70 (3) ◽  
pp. 307 ◽  
Author(s):  
Youyang Zhan ◽  
Rong Xue ◽  
Mengchao Zhang ◽  
Chuanling Wan ◽  
Xiaojing Li ◽  
...  
Keyword(s):  
Contrast Agent ◽  
Mri Contrast Agent ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Gadolinium Chelate ◽  
Liver Specific Contrast Agent ◽  
Magnetic Resonance Imaging Mri ◽  
Gadolinium Compound

A new macromolecular biocompatible gadolinium chelate complex (PAI-N2-DOTA-Gd) as a liver-specific magnetic resonance imaging (MRI) contrast agent was synthesised and evaluated. An aspartic acid–isoleucine copolymer was chemically linked with Gd-DOTA via ethylenediamine to give PAI-N2-DOTA-Gd. In vitro, the T1-relaxivity of PAI-N2-DOTA-Gd (14.38 mmol–1⋅L⋅s–1, 0.5 T) was much higher than that of the clinically used Gd-DOTA (4.96 mmol–1⋅L⋅s–1, 0.5 T), with obvious imaging signal enhancement. In the imaging experiments in vivo, PAI-N2-DOTA-Gd exhibited good liver selectivity, and had a greater intensity enhancement (68.8 ± 5.6 %) and a longer imaging window time (30–70 min), compared to Gd-DOTA (21.1 ± 5.3 %, 10–30 min). Furthermore, the in vivo histological studies of PAI-N2-DOTA-Gd showed a low acute toxicity and desirable biocompatibility. The results of this study indicate that PAI-N2-DOTA-Gd is a feasible liver-specific contrast agent for MRI.

Sign in / Sign up

Export Citation Format

Share Document